Evidence map›Paper›PMID 34943970›Full record

ArticleCells2021

Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer.

Shilpa Patil, Teresa Forster, Kristina Reutlinger, Waltraut Kopp, Lennart Versemann, Jessica Spitalieri, Jochen Gaedcke, Philipp Ströbel, Shiv K Singh, Volker Ellenrieder and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Cancers · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Shilpa PatilDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany.ORCID 0000-0001-8412-362X
Teresa ForsterDepartment of Gastroenterology, Endocrinology, Metabolism and Clinical Infectiology, Philipps University Marburg, 35043 Marburg, Germany.
Kristina ReutlingerDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany.
Waltraut KoppDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany.
Lennart VersemannDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany.
Jessica SpitalieriDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany.
Jochen GaedckeClinical Research Unit KFO5002, University Medical Center Goettingen, 37075 Goettingen, Germany.ORCID 0000-0002-6130-5874
Philipp StröbelClinical Research Unit KFO5002, University Medical Center Goettingen, 37075 Goettingen, Germany.
Shiv K SinghDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany.ORCID 0000-0002-5725-4058
Volker EllenriederDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany.
Albrecht NeesseDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany.
Elisabeth HessmannDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany.
University of Göttingen · DEPhilipps University of Marburg · DE

Funding

Deutsche Forschungsgemeinschaft KFO5002German Cancer Aid 70112108German Cancer Aid 70112505German Cancer Aid 70112999German Cancer Aid 70113213Volkswagen-Stiftung/Ministry for Culture and Science in Lower Saxony 11-76251-12-3/16Wilhelm-Sander-Stiftung 2017.107.1
6 · The paper itself

Abstract

backgroundThe Nuclear Factor of Activated T-cells 1 (NFATc1) transcription factor and the methyltransferase Enhancer of Zeste Homolog 2 (EZH2) significantly contribute to the aggressive phenotype of pancreatic ductal adenocarcinoma (PDAC). Herein, we aimed at dissecting the mechanistic background of their interplay in PDAC progression.

methodsNFATc1 and EZH2 mRNA and protein expression and complex formation were determined in transgenic PDAC models and human PDAC specimens. NFATc1 binding on the

resultsNFATc1 targets the

conclusionOur findings disclose a previously unknown NFATc1-EZH2 axis operational in the pancreas and provide mechanistic insights into the conditions fostering NFATc1:EZH2 complex formation in PDAC.

Indexed as

AnimalsCarcinoma, Pancreatic DuctalCell ProliferationChromatinDisease Models, AnimalEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansMiceNFATC Transcription FactorsPancreasPancreatic NeoplasmsProtein Processing, Post-TranslationalProto-Oncogene Proteins p21(ras)RNA, Small InterferingChromatinEnhancer of Zeste Homolog 2 ProteinEzh2 protein, mouseHomeodomain ProteinsHras protein, mouseNfatc1 protein, mouseNFATC Transcription Factorspancreatic and duodenal homeobox 1 proteinProto-Oncogene Proteins p21(ras)RNA, Small InterferingTrans-ActivatorschromatinEZH2NFATc1pancreatic cancerposttranslational EZH2 modification

Identifiers

PMID34943970
PMCPMC8700089
OpenAlexW4200045179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.